Immuneering (IMRX) Operating Income (2020 - 2026)

Immuneering's Operating Income history runs 7 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• In Q1 2026, Operating Income rose 0.97% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at -$59.2 million (up 7.79% YoY), while the FY2025 annual figure was -$59.4 million, up 7.33% from the prior year.
• Operating Income was -$15.3 million for Q1 2026 at Immuneering, down from -$13.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$11.6 million in Q2 2022 to a low of -$18.6 million in Q4 2024.
• Historically, Operating Income has averaged -$14.6 million across 5 years, with a median of -$14.8 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Operating Income sank 107.27% in 2022, then grew 25.89% in 2025.
• A 5-year view of Operating Income shows it stood at -$14.0 million in 2022, then declined by 16.57% to -$16.3 million in 2023, then declined by 13.84% to -$18.6 million in 2024, then increased by 25.89% to -$13.8 million in 2025, then declined by 11.51% to -$15.3 million in 2026.
• The last three Operating Income figures came in at -$15.3 million (Q1 2026), -$13.8 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.